Sierra Oncology Company Profile (NASDAQ:DNAI)

About Sierra Oncology (NASDAQ:DNAI)

Sierra Oncology logoSierra Oncology, Inc., formerly ProNAi Therapeutics, Inc., is a clinical-stage drug development company. The Company's lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network. SRA737 is being investigated in approximately two Phase I clinical trials in patients with advanced cancer. Sierra Oncology is also advancing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase (Cdc7) kinase undergoing preclinical development. Sierra is building a range of pipeline of various oncology assets against targets at the edge of cancer biology. The Company's SRA737 and SRA141 target the DDR network, a scientifically approach with far-reaching potential across oncology. SRA141 is an orally available small molecule inhibitor of Cdc7.

Industry, Sector and Symbol: Average Prices:
  • 50 Day Moving Avg: $1.48
  • 200 Day Moving Avg: $1.72
  • 52 Week Range: $1.32 - $10.37
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.33
  • P/E Growth: 0.00
Profitability:
  • Return on Equity: -35.50%
  • Return on Assets: -33.93%
Misc:
  • Average Volume: 556,061 shs.
 

Frequently Asked Questions for Sierra Oncology (NASDAQ:DNAI)

What is Sierra Oncology's stock symbol?

Sierra Oncology trades on the NASDAQ under the ticker symbol "DNAI."

When will Sierra Oncology make its next earnings announcement?

Sierra Oncology is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Sierra Oncology.

Where is Sierra Oncology's stock going? Where will Sierra Oncology's stock price be in 2017?

1 analysts have issued twelve-month price targets for Sierra Oncology's shares. Their predictions range from $4.00 to $4.00. On average, they anticipate Sierra Oncology's share price to reach $4.00 in the next twelve months. View Analyst Ratings for Sierra Oncology.

Who are some of Sierra Oncology's key competitors?

Who are Sierra Oncology's key executives?

Sierra Oncology's management team includes the folowing people:

  • Donald R. Parfet, Independent Chairman of the Board
  • Nicholas R. Glover Ph.D., President, Chief Executive Officer, Director
  • Sukhi Jagpal, Chief Financial Officer
  • Barbara Klencke M.D., Chief Development Officer
  • Mark Kowalski M.D. Ph.D., Chief Medical Officer
  • Angie J. You Ph.D., Chief Business & Strategy Officer and Head of Commercial
  • Jeffrey H. Cooper, Independent Director
  • Daniel Estes Ph.D., Independent Director
  • Tran Nguyen, Independent Director
  • Nicole Onetto M.D., Independent Director

When did Sierra Oncology IPO?

(DNAI) raised $100 million in an IPO on Thursday, July 16th 2015. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Jefferies and BofA Merrill Lynch served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

How do I buy Sierra Oncology stock?

Shares of Sierra Oncology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sierra Oncology's stock price today?

One share of Sierra Oncology stock can currently be purchased for approximately $1.56.


MarketBeat Community Rating for Sierra Oncology (NASDAQ DNAI)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  33 (Vote Outperform)
Underperform Votes:  29 (Vote Underperform)
Total Votes:  62
MarketBeat's community ratings are surveys of what our community members think about Sierra Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Sierra Oncology (NASDAQ:DNAI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.00 (156.41% upside)
Consensus Price Target History for Sierra Oncology (NASDAQ:DNAI)
Price Target History for Sierra Oncology (NASDAQ:DNAI)
Analysts' Ratings History for Sierra Oncology (NASDAQ:DNAI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/6/2017WedbushReiterated RatingOutperform$4.00N/AView Rating Details
(Data available from 10/21/2015 forward)

Earnings

Earnings History for Sierra Oncology (NASDAQ:DNAI)
Earnings by Quarter for Sierra Oncology (NASDAQ:DNAI)
Earnings History by Quarter for Sierra Oncology (NASDAQ DNAI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017N/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sierra Oncology (NASDAQ:DNAI)
Current Year EPS Consensus Estimate: $-1.55 EPS
Next Year EPS Consensus Estimate: $-1.17 EPS

Dividends

Dividend History for Sierra Oncology (NASDAQ:DNAI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Sierra Oncology (NASDAQ:DNAI)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Sierra Oncology (NASDAQ:DNAI)
Latest Headlines for Sierra Oncology (NASDAQ:DNAI)
Source:
DateHeadline
seekingalpha.com logoSierra Oncology (SRRA) Presents At 2017 BIO Investor Forum - Slideshow
seekingalpha.com - October 19 at 6:36 PM
seekingalpha.com logoSierra Oncology (SRRA) Updates on Next Generation DDR Therapeutics - Slideshow
seekingalpha.com - September 20 at 6:46 PM
seekingalpha.com logoRevisiting The ProNAi/Sierra Oncology Thesis 1 Year Later: Still Not Dead In The Water?
seekingalpha.com - July 17 at 11:55 PM
biz.yahoo.com logoSIERRA ONCOLOGY, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Even
biz.yahoo.com - January 11 at 5:16 PM
us.rd.yahoo.com logoFINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against ProNAi Therapeutics, Inc. (DNAI) and Lead Plaintiff Deadline - January 9, 2017
us.rd.yahoo.com - January 9 at 4:37 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of a Class Action Lawsuit Against ProNAi Therapeutics, Inc. and a Lead Plaintiff Deadline of January 9, 2017 – DNAI
us.rd.yahoo.com - January 4 at 5:49 PM
businesswire.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Commencement of a Class Action Lawsuit Against ProNAi Therapeutics, Inc. and a Lead Plaintiff Deadline of January ...
www.businesswire.com - December 30 at 1:42 AM
us.rd.yahoo.com logoSHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against ProNAi Therapeutics, Inc. (DNAI) and Lead Plaintiff Deadline - January 9, 2017
us.rd.yahoo.com - December 22 at 10:00 PM
businesswire.com logoDNAI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class ... - Business Wire (press release)
www.businesswire.com - December 22 at 3:35 AM
businesswire.com logoDNAI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving ProNAi Therapeutics, Inc. and a Lead Plaintiff Deadline of ...
www.businesswire.com - December 21 at 5:34 PM
benzinga.com logoIMPORTANT SHAREHOLDER ALERT: Khang & Khang...
www.benzinga.com - December 18 at 3:02 AM

Social

Chart

Sierra Oncology (DNAI) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.